Psoriasis patients utilizing secukinumab, ixekizumab, or brodalumab – comparisons to prior biologic medication adherence levels, reasons for switching, and reported changes in disease symptoms

Background: Since the approval of interleukin-17 (IL-17) inhibitors to treat psoriasis progression, an increasing number of patients have switched to these third-generation biologics (i.e. secukinumab, ixekizumab, or brodalumab). Little is known about the impact of the new therapy choices upon patie...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Drug Assess
Main Authors: Baiano, Renee, Staskon, Francis, Miller, Rick
Format: Artigo
Sprog:Inglês
Udgivet: Taylor & Francis 2019
Fag:
Poster #2
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6764379/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21556660.2019.1658298
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker